Registration
Advertiser Disclosure

DNA medicines, vaccine development, and biotechnology research by Inovio

INOVIO Pharmaceuticals to release third quarter financial results on November 10
  • Eugene Komchuk
  • 21 hours ago
INOVIO Pharmaceuticals to release third quarter financial results on November 10
INOVIO Pharmaceuticals announced it will report its third quarter 2026 financial results on Tuesday, November 10 after market close. The company will host a conference call at 4:30 p.m. ET to ...
FDA approves INOVIO Pharmaceuticals DNA-based treatment to reduce surgery need in RRP
  • Hanna Syniavska
  • 31.10.2026
FDA approves INOVIO Pharmaceuticals DNA-based treatment to reduce surgery need in RRP
INOVIO Pharmaceuticals announced that it has received accelerated approval from the FDA for its plasmid DNA-based immunotherapy. The newly approved therapy is designed to reduce the frequency of ...
INOVIO Pharmaceuticals to join investor conferences with webcast presentations and meetings
  • Ksenia Gerey
  • 02.09.2026
INOVIO Pharmaceuticals to join investor conferences with webcast presentations and meetings
INOVIO Pharmaceuticals announced its participation in several upcoming investor conferences, where the management team will deliver webcast presentations and hold one-on-one meetings with ...
Second quarter 2026 earnings and operations update released by INOVIO Pharmaceuticals
  • Andrey Mastykin
  • 12.08.2026
Second quarter 2026 earnings and operations update released by INOVIO Pharmaceuticals
INOVIO Pharmaceuticals has published its financial results and operational update for the second quarter of 2026. The company’s announcement highlights key figures and business developments ...
INOVIO Pharmaceuticals to present new protein replacement therapeutics research at WODC 2026
  • Ivan Andriyenko
  • 08.06.2026
INOVIO Pharmaceuticals to present new protein replacement therapeutics research at WODC 2026
INOVIO Pharmaceuticals has announced plans to participate in the World Orphan Drug Congress (WODC) 2026, where it will focus on rare disease protein replacement therapeutics and advancements in ...
INOVIO Pharmaceuticals advances INO-3107 immune therapy research for RRP
  • Elena Nikulina
  • 27.05.2026
INOVIO Pharmaceuticals advances INO-3107 immune therapy research for RRP
INOVIO Pharmaceuticals announced its participation at ASCO26 this week, unveiling additional data related to its lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP). According ...
INOVIO Pharmaceuticals posts first quarter 2026 results and reviews operations
  • Elena Nikulina
  • 13.05.2026
INOVIO Pharmaceuticals posts first quarter 2026 results and reviews operations
INOVIO Pharmaceuticals has released its financial results and operational overview for the first quarter of 2026. The company provided insights into its recent performance, with investors and ...
DPROT platform could enable sustained protein production for Hemophilia A, INOVIO Pharmaceuticals contends
  • Eugene Komchuk
  • 11.05.2026
DPROT platform could enable sustained protein production for Hemophilia A, INOVIO Pharmaceuticals contends
INOVIO Pharmaceuticals is presenting preclinical data on its next generation DPROT technology for Hemophilia A at ASGCT2026 this week. According to the company, DRPOTs may facilitate continuous ...
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers